Qiagen (QGEN) reported $532.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.1%. EPS of $0.61 for the same period compares to $0.59 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $525.99 million, representing a surprise of +1.25%. The company delivered an EPS surprise of +5.17%, with the consensus EPS estimate being $0.58.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus $34.77 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +14.3% change.
- Sales by Product Groups- Diagnostic solutions- QuantiFERON: $136 million versus $133.3 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.5% change.
- Sales by Product Groups- Diagnostic solutions- Other: $41 million compared to the $39.24 million average estimate based on three analysts. The reported number represents a change of 0% year over year.
- Sales by Product Groups- Other: $18 million versus the three-analyst average estimate of $17.37 million. The reported number represents a year-over-year change of +28.6%.
- Sales by Product Groups- PCR / Nucleic acid amplification: $75 million compared to the $76.5 million average estimate based on three analysts. The reported number represents a change of +1.4% year over year.
- Sales by Product Groups- Genomics / NGS: $61 million versus the three-analyst average estimate of $60.62 million. The reported number represents a year-over-year change of +10.9%.
- Sales by Product Groups- Diagnostic solutions: $209 million versus $207.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
- Sales by Product Groups- Sample technologies: $170 million compared to the $163.77 million average estimate based on three analysts. The reported number represents a change of +4.9% year over year.
View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned -2.7% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
